Myra Vision has filed a notice of an exempt offering of securities to raise $24,999,995.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Myra Vision is raising $24,999,995.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Robert Chang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Myra Vision
Designed to be the first-of-its-kind treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma. Myra Vision, a privately held portfolio company of Shifamed LLC, is developing a novel technology that is designed to allow safe outflow control to achieve maximum reduction of intraocular pressure (IOP) while also reducing complexity and complication rates.
To learn more about Myra Vision, visit http://www.myravision.com/
Contact:
Robert Chang, President and Chief Executive Officer
408-560-2500
https://www.linkedin.com/in/robert-chang-1a58115/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.